SuperworthSenti Biosciences SNTI
- Market cap
- $5.9M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Senti Biosciences' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $338K−81% | $0 | $0 | $0 | $0 | $0 | $0 | $0 | n/a | n/a | $16K | $17K | |
| R&D | $9.1M+40% | $9.1M−0% | $8.8M+24% | $9.2M+33% | $8.7M−5% | $7.8M−15% | $9.3M+6% | $10M+10% | $10.5M+22% | $7.8M−0% | $5.3M−43% | $7.8M−23% |
| SG&A | $9.4M−6% | $9.3M−5% | $7.5M−18% | $4.2M−55% | $6.6M−30% | $8.1M−13% | $7.1M−5% | $6.8M+61% | $6.4M−2% | $5.8M−28% | $6.2M−12% | $6.7M−0% |
| −$43.9M+198% | −$18.7M−7% | −$16.3M+9% | −$13.4M−12% | −$15.2M−65% | −$16.2M−14% | −$16.4M+1% | −$16.8M+26% | −$16.9M+11% | −$18.6M+15% | −$4.6M−72% | −$14.5M−14% | |
| Net income | −$14.9M−10% | −$18.7M+3% | −$12.1M−35% | −$11.2M−40% | −$28.9M+93% | −$610K−97% | −$14.1M+17% | −$14.7M+32% | −$18.1M−37% | −$14.5M+2272% | −$4.2M−70% | −$12.8M−14% |
| −$3.36−12% | −$4.19−0% | −$2.65−37% | −$2.45−42% | −$6.31+88% | −$0.67−84% | −$1.41−47% | −$0.56−77% | −$0.69−89% | −$0.53−21% | −$0.14−90% | −$0.41−27% | |
| 4.4M+2% | 4.5M+2% | 4.6M+4% | 4.6M+3% | 4.6M+3% | 4.7M+4% | 10M+119% | 26.1M+471% | 26.2M+473% | 27.4M+487% | 31M+209% | 31.1M+19% |
EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY21 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Senti Biosciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SNTISenti Biosciences | $5.9M | n/m | n/a | n/m | n/m | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| Peer median | $47.8M | 13.6× | 14.8× | 1.4× | +15% | 7.6% |
More on Senti Biosciences
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .